NONMEM Users Network Archive

Hosted by Cognigen

[NMusers] Job Opening _at_ Memorial Sloan Kettering Cancer Center (New York City)

From: Krekels, E.H.J. <>
Date: Mon, 4 Feb 2019 09:12:53 +0000

On behalf of Jaap Jan Boelens I would like to draw your attention to the fo=
llowing position. If you are interested or have questions, please contact h=
im directly on the e-mail address provided below.

The adult and pediatric 'stem cell transplant and cellular therapy service'=
, perform combined over 250 allogeneic hematopoietic cell transplantations =
per year, and over 100 cellular therapies (e.g. CART, virus spec. CTLs). We=
 are recruiting a 'population PK-PD' modeler to be part of a 'PK-PD and Imm=
une monitoring core' (which currently being developed), linked to both clin=
ical programs. A 'tenured track' position would be an option.

Description: We are recruiting a 'population PK-PD modeler' with special in=
terest in cell and gene-therapy: modeling (multi-) agents used in condition=
ing, antibodies, 'immune effector cells' and immune monitoring. In the adul=
t and pediatric 'SCT and Cell therapy services" there is a long-standing in=
terest using PK-modeling to individualize treatment, to reduce toxicity and=
 improve efficacy. With the recent appointment of Dr JJ Boelens as new chie=
f of the pediatric program, the interest has further increased. Dr Boelens =
has spearheaded various projects to individualize (e.g. Busulfan, ATG, Flud=
arabine) and harmonize conditioning regimens aiming for better predictable =
immune reconstitution and outcomes. The mission of the both services (adul=
t and pediatrics) is to improve survival chances and 'quality of life' of p=
atients in need for a cell- or gene-therapy to cure cancer (at MSK and worl=
dwide) by customizing / precision their treatment. To achieve this, we are =
building the most innovative, flexible advanced 'Good Laboratory Practice (=
GLP)"-approved "PK-PD and immune monitoring" core. By implementing state-of=
-the-art technologies to measure drug levels and identify rare cell types a=
t levels not detectable by conventional clinical instruments, this strategy=
 both decreases toxicity, with minimal effect on 'quality of life', and inc=
reases the chances of disease-free survival.
Opportunities for teaching, translational research, and multidisciplinary c=
ollaborative projects are numerous.

Rank and salary will be based on background and experience.

Interested and qualified applicants should send their CV and bibliographies=
 Dr Jaap Jan Boelens (Chief of Service):<mailto:boelensj=>

Received on Mon Feb 04 2019 - 04:12:53 EST

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to: Once subscribed, you may contribute to the discussion by emailing: